NCT05140954 - The Women TAF-FTC Benchmark Study | Biotech Hunter

Enrollment

Participants

Timeline

Start Date

April 10, 2023

Primary Completion Date

December 19, 2023

Study Completion Date

December 19, 2023

Conditions

HIV Infections

Interventions

DRUG

co-formulated 25mg TAF/ 200mg FTC

Participants will be randomized into 1 of 3 groups to receive a controlled number of doses of a single tablet co-formulated 25 mg TAF/ 200mg FTC

Trial Locations (1)

Kenya Medical Research Institute - Partners in Health Research and Development, Thika